Within this range, 0–9 days after onset of symptoms, patients with mild COVID-19 showed an increased CD169/SIGLEC1 expression compared to patients with severe COVID-19, and also compared to SARS-CoV-2 negative patients (p < 0.0001 for both comparisons, Fig. 1a). This evidence concerns the gene SIGLEC1 and COVID-19.